Clinical Trials

A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma.


Study ID
MRNA-4157-P201

NCT Number
NCT03897881 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0319

Principle Investigator
Dr. Pecora, Andrew

Phase
II

Sponsor
Moderna Therapeutics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now